AR045389A1 - Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido - Google Patents
Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituidoInfo
- Publication number
- AR045389A1 AR045389A1 ARP040103010A ARP040103010A AR045389A1 AR 045389 A1 AR045389 A1 AR 045389A1 AR P040103010 A ARP040103010 A AR P040103010A AR P040103010 A ARP040103010 A AR P040103010A AR 045389 A1 AR045389 A1 AR 045389A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyclyl
- optionally substituted
- heterocyclyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49676603P | 2003-08-21 | 2003-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045389A1 true AR045389A1 (es) | 2005-10-26 |
Family
ID=34272512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103010A AR045389A1 (es) | 2003-08-21 | 2004-08-20 | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido |
Country Status (19)
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
JPWO2007052849A1 (ja) | 2005-11-07 | 2009-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質とc−kitキナーゼ阻害物質との併用 |
JP5583346B2 (ja) * | 2006-01-18 | 2014-09-03 | エルジー ハウスホールド アンド ヘルスケア リミテッド | c−Kit活性阻害剤、及び、肌美白剤 |
TW200740776A (en) * | 2006-02-06 | 2007-11-01 | Osi Pharm Inc | N-phenylbenzotriazolyl c-kit inhibitors |
CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
JPWO2012121168A1 (ja) * | 2011-03-04 | 2014-07-17 | 国立大学法人京都大学 | キナーゼ阻害剤 |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
JP6423372B2 (ja) | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体 |
SG11201509278XA (en) | 2013-05-14 | 2015-12-30 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
AR096654A1 (es) * | 2013-06-20 | 2016-01-27 | Ab Science | Derivados de benzimidazol como inhibidores selectivos de proteína quinasa |
IL302218B1 (en) | 2014-08-28 | 2024-06-01 | Eisai R&D Man Co Ltd | Methods for the production of lanvotinib and its derivatives in a high degree of purity |
DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
GB8610980D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Heterocyclic fused tricyclic compounds |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
AU685881B2 (en) | 1994-02-10 | 1998-01-29 | Pfizer Inc. | 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists |
US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
EP0846689B1 (en) | 1996-12-09 | 2004-01-14 | Pfizer Inc. | Benzimidazole compounds |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
US6348474B1 (en) | 1997-06-27 | 2002-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6444617B1 (en) | 1998-07-28 | 2002-09-03 | Nihon Nohyaku Co., Ltd. | Fused-heterocycle dicarboxylic acid diamide derivatives or salts thereof, herbicide and usage thereof |
AU760020B2 (en) | 1998-08-31 | 2003-05-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
US6348032B1 (en) * | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
US6329383B1 (en) | 1999-01-25 | 2001-12-11 | Pharmacia Ab | 2-amino-5-pyrimidine acetic acid compounds |
EP1165517A1 (en) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators |
CO5190696A1 (es) | 1999-06-16 | 2002-08-29 | Smithkline Beecham Corp | Antagonistas de los receptores il-8 |
WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
DE19939463A1 (de) | 1999-08-20 | 2001-02-22 | Boehringer Ingelheim Pharma | Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP1085372B1 (en) | 1999-09-13 | 2004-12-22 | Eastman Kodak Company | Photographic material having improved color reproduction |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
US6316474B1 (en) | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
WO2001057019A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
US20020072530A1 (en) | 2000-02-01 | 2002-06-13 | Bing-Yan Zhu | Indole and benzimidazole inhibitors of factor Xa |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
WO2002030886A2 (en) | 2000-10-12 | 2002-04-18 | Matthews Barry R | Heterocyclic angiogenesis inhibitors |
CZ20031910A3 (cs) | 2000-12-11 | 2003-12-17 | Tularik Inc. | Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek |
GB0102109D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
CA2440037C (en) | 2001-03-05 | 2010-02-16 | Transtech Pharma, Inc. | Benzimidazole derivatives for modulating the rage receptor |
WO2002072090A1 (en) | 2001-03-12 | 2002-09-19 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
WO2002076960A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transition metal mediated process |
-
2004
- 2004-08-16 DE DE602004017623T patent/DE602004017623D1/de active Active
- 2004-08-16 WO PCT/US2004/026481 patent/WO2005021537A1/en active Application Filing
- 2004-08-16 JP JP2006523954A patent/JP4795237B2/ja not_active Expired - Fee Related
- 2004-08-16 CN CNA2004800239977A patent/CN1839130A/zh active Pending
- 2004-08-16 CA CA002536151A patent/CA2536151A1/en not_active Abandoned
- 2004-08-16 RU RU2006108791/04A patent/RU2006108791A/ru not_active Application Discontinuation
- 2004-08-16 UA UAA200602943A patent/UA84712C2/ru unknown
- 2004-08-16 BR BRPI0413785-0A patent/BRPI0413785A/pt not_active IP Right Cessation
- 2004-08-16 AU AU2004268948A patent/AU2004268948A1/en not_active Abandoned
- 2004-08-16 AP AP2006003553A patent/AP2006003553A0/xx unknown
- 2004-08-16 KR KR1020067003094A patent/KR20060115346A/ko not_active Application Discontinuation
- 2004-08-16 AT AT04781203T patent/ATE413395T1/de not_active IP Right Cessation
- 2004-08-16 EP EP04781203A patent/EP1664032B1/en active Active
- 2004-08-16 MX MXPA06002017A patent/MXPA06002017A/es unknown
- 2004-08-20 AR ARP040103010A patent/AR045389A1/es not_active Application Discontinuation
- 2004-08-20 TW TW093125240A patent/TW200524911A/zh unknown
-
2006
- 2006-02-08 IL IL173616A patent/IL173616A0/en unknown
- 2006-02-10 NO NO20060665A patent/NO20060665L/no not_active Application Discontinuation
- 2006-02-21 IS IS8320A patent/IS8320A/is unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005021537A1 (en) | 2005-03-10 |
NO20060665L (no) | 2006-05-16 |
BRPI0413785A (pt) | 2006-11-07 |
UA84712C2 (en) | 2008-11-25 |
AU2004268948A1 (en) | 2005-03-10 |
MXPA06002017A (es) | 2006-05-31 |
TW200524911A (en) | 2005-08-01 |
KR20060115346A (ko) | 2006-11-08 |
EP1664032A1 (en) | 2006-06-07 |
DE602004017623D1 (de) | 2008-12-18 |
RU2006108791A (ru) | 2006-07-27 |
CN1839130A (zh) | 2006-09-27 |
CA2536151A1 (en) | 2005-03-10 |
EP1664032B1 (en) | 2008-11-05 |
JP4795237B2 (ja) | 2011-10-19 |
JP2007502820A (ja) | 2007-02-15 |
AP2006003553A0 (en) | 2006-04-30 |
IL173616A0 (en) | 2006-07-05 |
ATE413395T1 (de) | 2008-11-15 |
IS8320A (is) | 2006-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
AR048346A1 (es) | Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central. | |
PE20131377A1 (es) | Triazina-oxadiazoles | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
IL272762B1 (en) | Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases | |
DE602005022764D1 (de) | Piperidin- und azetidinderivate als glyt1-inhibitoren | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
PE20141067A1 (es) | Compuestos para el tratamiento de la adiccion | |
AR066972A1 (es) | Derivados azapeptidicos | |
PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
AR087355A1 (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |